Randomized trial demonstrates durable remission with CTL019 therapy in refractory B-cell lymphomas, highlighting cellular immunotherapy efficacy alongside notable toxicities.
CTL019 cells can be effective in the treatment of relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. High rates of durable remission were observed, with recovery of B cells and immunoglobulins in some patients. Transient encephalopathy developed in approximately one in three patients and severe cytokine-release syndrome developed in one in five patients. (Funded by Novartis and others; ClinicalTrials.gov number, NCT02030834 .).
No takes yet. Share an insight, caveat, or question.
Schuster et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: